Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.81 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | PGR | P06401 | 2/20 | 0.81 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | SHBG | P04278 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL6447755 | 1.00 | HIF1A (0.81) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL27628953 | 0.93 | NR3C1 (0.85) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| SCHEMBL2472390 | 0.91 | HIF1A (0.71) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| SCHEMBL18278997 | 0.90 | HIF1A (0.80) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL3999007 | 0.90 | HIF1A (0.96) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL24900238 | 0.90 | HIF1A (1.00) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL10292969 | 0.90 | HIF1A (1.00) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL13202859 | 0.90 | HIF1A (1.00) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL13046615 | 0.90 | HIF1A (1.00) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 | |
| Hydrocortisone SCHEMBL15114813 | 0.90 | HIF1A (1.00) | HIF1ANR3C1NR3C2CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| EP-1827408-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1827400-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1814540-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | Nu-Tein Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| WO-2006062740-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006060475-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006055526-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | NU-TEIN CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | NR3C1 1801/4885HIF1A 931/4885NR3C2 1148/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | NR3C1 3349/4885HIF1A 387/4885NR3C2 1852/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | NR3C1 4858/4885HIF1A 2552/4885NR3C2 4871/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | NR3C1 3140/4885HIF1A 923/4885NR3C2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.